19 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
27
Development of novel CXC chemokine receptor 7 (CXCR7) ligands: selectivity switch from CXCR4 antagonists with a cyclic pentapeptide scaffold.
Kyoto University
23
Optimized method of G-protein-coupled receptor homology modeling: its application to the discovery of novel CXCR7 ligands.
Pharmadesign
24
Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists.
Vu University Amsterdam
5
Disulfide bond replacement with non-reducible side chain to tail macrolactamization for the development of potent and selective CXCR4 peptide antagonists endowed with flanking binding sites.
University of Naples "Federico II"
37
Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation.
Eberhard Karls University T£Bingen
23
Discovery and evaluation of non-basic small molecule modulators of the atypical chemokine receptor CXCR7.
Pfizer
95
Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239.
Idorsia Pharmaceuticals
4
Discovery of Diphenylacetamides as CXCR7 Inhibitors with Novel β-Arrestin Antagonist Activity.
Pfizer
4
Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68).
Icahn School Of Medicine At Mount Sinai
10
Discovery, Synthesis, Pharmacological Profiling, and Biological Characterization of Brintonamides A-E, Novel Dual Protease and GPCR Modulators from a Marine Cyanobacterium.
University of Florida
17
Discovery of a Novel Small-Molecule Modulator of C-X-C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis.
Pfizer
60
Structure-Activity Relationship Study of Cyclic Pentapeptide Ligands for Atypical Chemokine Receptor 3 (ACKR3).
Kyoto University
68
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists.
Gsk Pharmaceuticals R & D
27
Discovery of Potent and Orally Bioavailable Macrocyclic Peptide-Peptoid Hybrid CXCR7 Modulators.
Pfizer
219
SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS
Boehringer Ingelheim International
175
Sars-cov-2 inhibitors having covalent modifications for treating coronavirus infections
Insilico Medicine IP
17
2,4,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors
Korea Institute of Science and Technology
25
Synthesis, biological evaluation and docking studies of 2,3-dihydroquinazolin-4(1H)-one derivatives as inhibitors of cholinesterases.
University of Sargodha